CABA – cabaletta bio, inc. (US:NASDAQ)
Stock Stats
News
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "outperform" rating re-affirmed by analysts at William Blair.
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 [Yahoo! Finance]
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $12.00. They now have an "overweight" rating on the stock.
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Form 8-K Cabaletta Bio, Inc. For: Nov 18
Form SC 13G/A Cabaletta Bio, Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.
Form SC 13G/A Cabaletta Bio, Inc. Filed by: ALGER ASSOCIATES INC
Form SC 13G Cabaletta Bio, Inc. Filed by: T. Rowe Price Investment Management, Inc.
Form 10-Q Cabaletta Bio, Inc. For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.